Implementing the Eczema Society’s Practical Management Guide into Your Practice - Ordre des pharmaciens du Québec (OPQ)
Eczema Management for Pharmacists
Atopic dermatitis (AD) is a chronic, relapsing, and remitting inflammatory skin disease characterized by erythema, edema, xerosis, erosions/excoriations, oozing and crusting, and lichenification, with pruritus as the hallmark of the condition. This condition is very common and affects between 10% and 20% of children in developing countries.
Although once thought of as only a pediatric condition, data now shows that up to 10.2% patients have symptoms that persist into adulthood. A 3.2% prevalence of eczema, asthma, and hay fever was identified, suggesting AD is not uncommon in adult patients. Patient-reported rates of adult AD between 2.1% and 4.9%, most commonly of mild-to-moderate severity. A systematic review and meta-analysis suggests that there is no significant difference in AD prevalence before and after childhood.
This continuing education activity has been accredited by l'Ordre des Pharmaciens du Quebec, which will grant 1 credit to pharmacists who have completed it successfully.
Kirk Barber (MD, FRCPC)
Moe Abdallah (BSc., BSc. Pharm., R.Ph.)
Tom Smiley (BScPhm, PharmD, CTE)
On completion of this program, participants will be better able to:
- Identify both the molecular and clinical features of cystic fibrosis (CF) caused by the “residual function” (RF) mutations
- Describe the likely impact of genotype of both alleles on the total activity of the cystic fibrosis transmembrane conductance regulator (CFTR) protein
- Differentiate RF mutations from ‘minimal function (no detectable function)’ mutations with respect to their impact on phenotype and burden of illness
- Evaluate the safety and efficacy of tezacaftor/ivacaftor in the treatment of patients with RF mutations causing CF